NRAS and melanoma: While the difference observed in overall survival (OS) or disease-specific survival (DSS) was not significant between patients with high versus low ACKR2 expression across all melanoma cases (Figure 3(d)), the prognostic relevance of ACKR2 became evident in BRAF- and NRAS mutated melanoma (Figure 3(e,f)).